Andere talen Scandion Oncology A/S

Aandelen

SCOL

DK0061031895

Vertraagde tijd Nasdaq Stockholm Andere beurzen 13:44:31 20-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,394 ^SEK	+1,55%		-18,93%	-90,14%

22/05	Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
22/05	Scandion Oncology A/S rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Scandion announces change of Certified Adviser to Vator Securities	03/06
SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE	31/05
Scandion Oncology Q1 2024 - Funding for CORIST part 3 extension	27/05
Scandion Oncology – Interim Report Q1 2024	22/05
Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	22/05
Invitation to Scandion Oncology webcast and conference call May 22, 2024	16/05
Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101	13/05
Scandion Confirms Positive Final Phase Ib Data from Pantax Trial with Sco-101	13/05
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors	06/05
Scandion Oncology to Host R&D Update May 15	03/05
Scandion Oncology – Notice convening the Annual General Meeting	19/04
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival	21/03
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	21/03
Scandion Oncology - Annual Report 2023	15/03
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial	07/03
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	07/03
Scandion Oncology Q4 2023 - Striving towards randomised controlled data	01/03
Scandion Oncology – Q4 & yearend report 2023	28/02
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Scandion Oncology A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Scandion Oncology A/S

Aandelen

SCOL

DK0061031895

Andere talen

Filters